Compare TDW & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TDW | ACAD |
|---|---|---|
| Founded | 1956 | 1993 |
| Country | United States | United States |
| Employees | 7300 | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.8B |
| IPO Year | N/A | 2000 |
| Metric | TDW | ACAD |
|---|---|---|
| Price | $85.74 | $20.59 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 22 |
| Target Price | ★ $81.33 | $30.55 |
| AVG Volume (30 Days) | 744.9K | ★ 1.5M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $726,437,000.00 |
| Revenue This Year | $8.44 | $18.80 |
| Revenue Next Year | $12.34 | $11.70 |
| P/E Ratio | ★ $24.08 | $1,029.50 |
| Revenue Growth | N/A | ★ 40.45 |
| 52 Week Low | $38.24 | $19.69 |
| 52 Week High | $93.13 | $28.35 |
| Indicator | TDW | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 54.95 | 39.08 |
| Support Level | $80.29 | $20.06 |
| Resistance Level | $88.99 | $22.64 |
| Average True Range (ATR) | 3.23 | 0.78 |
| MACD | 0.01 | -0.18 |
| Stochastic Oscillator | 73.41 | 10.83 |
Tidewater Inc provides marine and transportation services to the offshore energy industry. The company's vessels and associated services support all phases of offshore crude oil and natural gas (also referred to as oil and gas) exploration activities, field development, production, and maintenance, as well as windfarm development and maintenance. Its services include towing and anchor handling for mobile offshore drilling units; transporting supplies and personnel necessary to sustain drilling, workovers, production activities, field abandonment, dismantlement, and restoration activities; and Others. The group manages its business through five segments, including the Americas, Asia Pacific, Middle East, Europe/Mediterranean, and West Africa.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.